Satoshi Kubo, MD, PhD

Department of Molecular Targeted Therapies (DMTT), University of Occupational and Environmental Health, Japan
Kitakyushu, Japan

2005 M.D.
2014 Ph.D.

Disclosure information not submitted.

Presentation(s):

• 1586: Sustained Remission Following the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis (XANADU Study): A Multicenter, Prospective, and Randomized Controlled Study

  Sunday, November 13, 2022
  3:15 PM – 3:25 PM Eastern Time